Table 1 Characteristics of 505 patients hospitalised with community-acquired pneumonia
Characteristics | All patients (n = 505) |
|---|---|
Age in years (SD) | 63.4 (18.0) |
Male sex (%) | 295 (58.4) |
Comorbidities (%) | |
Chronic obstructive pulmonary disease | 98 (19.4) |
Congestive heart failure | 68 (13.5) |
Renal disease | 40 (7.9) |
Diabetes mellitus | 77 (15.2) |
Liver disease | 2 (0.4) |
Pneumonia Severity Index class I-III (%) | 279 (55.2) |
Pneumonia Severity Index class IV-V (%) | 226 (44.8) |
Pathogens (%) | |
Streptococcus pneumoniae | 124 (24.6) |
Coxiella burnetii | 28 (5.5) |
Haemophilus influenzae | 27 (5.3) |
Legionella pneumophila | 20 (4.0) |
Chlamydophila species | 16 (3.2) |
Mycoplasma pneumoniae | 9 (1.8) |
Staphylococcus aureus | 9 (1.8) |
Only viral pathogen | 35 (6.9) |
Other pathogen | 27 (5.3) |
No pathogen identified | 210 (41.6) |
Empirical antibiotic treatment (%) | |
Beta-lactam, penicillins (monotherapy) | 254 (50.3) |
Other beta-lactam (monotherapy) | 86 (17.0) |
Beta-lactam, penicillins + quinolone | 34 (6.7) |
Beta-lactam, penicillins + macrolides | 33 (6.5) |
Other beta-lactam + aminoglycoside | 20 (4.0) |
Other beta-lactam + quinolone | 16 (3.2) |
Quinolone (monotherapy) | 11 (2.2) |
Macrolides, lincosamides and streptogramins (monotherapy) | 11 (2.2) |
Beta-lactam, penicillin + aminoglycoside | 7 (1.4) |
Other beta-lactam, penicillin + macrolides | 7 (1.4) |
Sulfanomides and trimethoprim (monotherapy) | 6 (1.2) |
Tetracyclines (monotherapy) | 6 (1.2) |
Other | 14 (2.8) |
Outcomes | |
Length of hospital stay (IQR) | 8.5 (6.0-13.0) |
Intensive care unit admission (%) | 38 (7.5) |
In-hospital mortality (%) | 24 (4.8) |
30-Day mortality (%) | 26 (5.1) |
One-year mortality (%) | 73 (14.5) ⟂ |